Search
Search Results
##search.searchResults.foundPlural##
-
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3982PDF: 1040HTML: 3579Untitled: 174Cneo. Fig.1: 111Untitled: 102Untitled: 125Untitled: 129 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2079PDF: 1663HTML: 366 -
IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME
3276PDF: 2261HTML: 23314Untitled: 201Untitled: 212Untitled: 227 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1349HTML: 386PDF: 812 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2147PDF: 1570HTML: 260 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1176PDF: 1058HTML: 190 -
FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT
4394PDF: 1621HTML: 3593Tables and Images: 215 -
-
SOLITARY PLASMACYTOMA
3821PDF: 2167HTML: 1215fIGURES 1,2: 209 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1219PDF: 973HTML: 202 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
2147PDF: 979HTML: 142Suppl. Files: 507 -
FDG-PET SCAN: A NEW PARADIGM FOR FOLLICULAR LYMPHOMA MANAGEMENT.
3296PDF: 1233HTML: 2193 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9011PDF: 6038HTML: 87935Fig.1b: 180Fig.1c: 184Fig.2a: 173Fig.2b: 172Fig.4: 186Fig.2c: 180Fig.3: 179Tab.1: 224Tab.2: 205Tab.3: 186Tab.4: 220Fig1a: 178 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3516PDF: 2392HTML: 1451 -
-
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1504PDF: 930HTML: 218 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7396PDF: 2411HTML: 1720Table 1.: 204Table 2.: 215Table 3.: 195Table 4.: 195 -
ASSOCIATION BETWEEN PRE-ADMISSION 48-HOUR FEVER BURDEN AND OUTCOMES IN PEDIATRIC MYCOPLASMA PNEUMONIAE INFECTION PRE-ADMISSION 48-HOUR FEVER BURDEN AND OUTCOMES IN PEDIATRIC MYCOPLASMA PNEUMONIAE
116PDF: 131Suppl. Files: 26HTML: 13 -
EFFICACY OF VENETOCLAX COMBINED WITH AZACITIDINE IN ELDERLY PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA
1441PDF: 751Suppl. Files: 320Html: 132 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2783PDF: 1002HTML: 5513 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3352PDF: 1276HTML: 2212Fi.1 Gritti.Rambaldi: 203 -
REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE
12318PDF: 1670HTML: 4161Cover letter: 195Figure 1: 201 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
462PDF: 239HTML: 77 -
THE CHALLENGE OF AML IN OLDER PATIENTS
2163PDF: 943HTML: 2152 -
DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES.
4773PDF: 1791HTML: 2125 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2122PDF: 1318HTML: 3497 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
3868Suppl. Files: 1098PDF: 1060Html: 170 -
Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited
1077PDF: 839HTML: 234 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1023PDF: 1147Suppl. Files: 569HTML: 79 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4291PDF: 1754HTML: 1104 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2866PDF: 1354HTML: 3564Untitled: 191Untitled: 199Untitled: 175 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1676PDF: 1156HTML: 242 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2015PDF: 816HTML: 208







